A Phase 2 interventional study of PD-0332991 and PD-0332991 in Neoplasms and Breast Neoplasms, sponsored by Pfizer. Completed at 16 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2020-11-23.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 111 studies testing palbociclib in Breast Neoplasms — 19 open to participants now, 43 under way, 9 of them phase 3. palbociclib · Breast Neoplasms.
Among the 111 studies testing palbociclib in Breast Neoplasms, this one is the 69th largest by enrollment, is one of 4 that started in 2012, is one of 62 in phase 2, and was the 5th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →19 of the 111 studies testing palbociclib in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Fudan University · Sites in China
Ages 18+
American Society of Clinical Oncology · Sites in United States
Ages 60+
Region Örebro County · Sites in Finland, Greece, Italy and 3 more countries
Ages 70+
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Sites in Germany
Ages 18+ · Women only
Northwestern University · Sites in United States
Ages 18+
By country, each count listing its studies:
palbociclib: first FDA approval 2015 (IBRANCE), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, palbociclib is the treatment under test here. Read study by study →
111 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 68 · Phase 3 21 · Phase 4 5
First in 2008; this study’s year is marked. 4 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 61 is below the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 100 across the 111 interventional studies. Of the 54 that completed or were terminated, 27 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 111 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
182 studies in Breast Neoplasms by Pfizer: 6 open now, 26 under way, 7 of them phase 3. Of 145 finished, 94 (65%) have results posted.
Among the 182 studies in Breast Neoplasms by Pfizer, this one is the 70th largest by enrollment of the 121 interventional ones that give a count, is one of 4 that started in 2012, is one of 43 in phase 2, and was the 68th registered.
Pfizer’s Breast Neoplasms studies by the year they started, since 1998.
13 of the studies testing palbociclib in Breast Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03820830Phase 3ETOP IBCSG Partners FoundationPalbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer | 2026-12 |
| NCT02605486Memorial Sloan Kettering Cancer CenterPalbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC) | 2026-11 |
| NCT02738866Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsPalbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor | 2026-12 |
| NCT07130643Xinhong Wu, PhDEfficacy and Safety of CDK4/6 Inhibitors Combined With Endocrine Therapy in HR+/HER2- Neoadjuvant Therapy for Early Breast Cancer | 2026-12-20 |
| NCT03573648Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNeoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer | 2026-12-30 |
Add all 13 to your calendar (.ics) → With an account.
Among the 111 studies testing palbociclib in Breast Neoplasms, from their registry updates:
Among Pfizer’s 182 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This study is comprised of two portions: a Phase 1 portion and a Phase 2 portion. The Phase 1 portion is a single-country, non-randomized, open label, clinical trial which will evaluate the safety, tolerability, preliminary efficacy, and PK profile of PD-0332991 as a single agent in Japanese patients with advanced solid tumors, and PD-0332991 in combination with letrozole in the first-line treatment of Japanese patients with ER(+) HER2(-) ABC. The Phase 2 portion is a single-country, non-randomized, open-label, single-cohort, multi-center clinical trial to evaluate the efficacy and safety of PD-0332991 in combination with letrozole for the first-line treatment of postmenopausal Japanese patients with ER(+) HER2(-) ABC.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
This study's enrollment of 61 is below the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Browse Breast Neoplasms studies →Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Compared within Breast Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Phase 1
Phase 2
Exclusion Criteria:
Phase 1
Phase 2
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Phase 1 Part 1
Drug: PD-0332991
Phase 1 Part 2
Drug: PD-0332991 · Drug: letrozole
Phase 2
Drug: PD-0332991 · Drug: letrozole
PD-0332991 (100 mg or 125 mg) will be orally administered once a day for 3 weeks followed by 1 week off treatment, in the morning on an empty stomach. Dose reduction of PD-0332991 by one (100 mg) or two (75 mg) dose level is permitted depending on treatment related toxicity.
PD-0332991, 125 mg, will be orally administered with food once a day for 3 weeks followed by 1 week off treatment. PD-0332991 will be administered once a day together with letrozole. Dose reduction of PD-0332991 by one (100 mg) or two (75 mg) dose level is permitted depending on treatment related toxicity.
Letrozole, 2.5 mg, will be orally administered once a day in continuous daily dosing together with PD-0332991. Dose reduction of letrozole is not permitted, but dosing interruptions for letrozole-related toxicity are allowed as per investigator's medical judgement.
PD-0332991, 125 mg, will be orally administered with food once a day for 3 weeks followed by 1 week off treatment. PD-0332991 will be administered once a day together with letrozole. Dose reduction of PD-0332991 by one (100 mg) or two (75 mg) dose level is permitted depending on treatment related toxicity.
Letrozole, 2.5 mg, will be orally administered once a day in continuous daily dosing together with PD-0332991. Dose reduction of letrozole is not permitted, but dosing interruptions for letrozole-related toxicity are allowed as per investigator's medical judgement.
Number of Participants With Dose Limiting Toxicities (DLT): Part 1 Phase 1
DLT was classified as per common terminology criteria for adverse events (CTCAE) version 4.0 as any of the events occurring during 28 days of Cycle 1,attributed to study drug:grade 4 neutropenia(for a duration of greater than \[\>\]7 days); febrile neutropenia (grade greater than or equal to \[\>=\]3 neutropenia,body temperature \>=38.5 degree Celsius);grade \>=3 thrombocytopenia with bleeding episode;grade 4 thrombocytopenia;grade \>=3 non-hematologic toxicity except grade 3 or more nausea, vomiting,electrolyte abnormality(if controllable by therapy);grade 3 QTc prolongation(\>500 millisecond \[msec\])persist after correction of reversible cause such as electrolyte abnormalities or hypoxia. Lack of hematologic recovery (platelets less than \[\<\]50,000/microliter \[mcL\],absolute neutrophil count \<1,000/mcL,hemoglobin \<8.0 gram/deciliter \[g/dL\]) or prolonged non hematologic toxicities that delays initiation of next dose by \>7 days;receipt of \<75 percent of planned dose in first cycle due to toxicity.
Time frame: Lead-in period (Day -7) up to Day 28 (Cycle 1)
Number of Participants With Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs): Part 2 Phase 1
A treatment related AE is any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event had a causal relationship with the treatment or usage. A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Relatedness was judged by investigator. AEs included both serious and non-serious adverse events.
Time frame: Baseline (Day 1) up to 28 days after last dose of study drug (up to 1673 days)
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) By Severity: Part 2 Phase 1
AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An AE was considered treatment emergent if occurred for the first time after the start of study treatment or occurred prior to the start of treatment but increased in National Cancer Institute (NCI) CTCAE grade during study treatment period. AE severity was defined to be the maximum toxicity grade of the TEAEs experienced by the participants during the study. AE was assessed according to severity as: Grade 1 (mild AE), Grade 2 (moderate AE), Grade 3 (severe AE), Grade 4 (life-threatening consequences) and Grade 5 (death related to AE).
Time frame: Baseline (Day 1) up to 28 days after last dose of study drug (up to 1673 days)
Percentage of Participants With 1 Year Progression Free Survival (PFS): Phase 2
PFS was defined as the time from first dose of study treatment to the date of the first documentation of objective progression of disease (PD) or death due to any cause in the absence of documented PD, whichever occurred first. PD was defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.1-year PFS was defined as the percentage of participants without PFS events (PD or death due to any cause) at 12 months based on the Kaplan-Meier estimate. Percentage of participants with 1-year PFS with 90% confidence interval (CI) were reported.
Time frame: From initiation of treatment up to 12 months
Number of Participants With Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs): Phase 1 (Part 1) and Phase 2
A treatment related AE is any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event had a causal relationship with the treatment or usage. A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Relatedness was judged by investigator. AEs included both serious and non-serious adverse events.
Time frame: Part 1 Phase 1: Lead-in period (Day -7) up to 28 days after last dose of study drug (up to 308 days), Phase 2: Baseline (Day 1) up to 28 days after last dose of study drug (up to 1526 days)
Number of Participants With Treatment-Emergent Adverse Events (AEs) By Severity: Phase 1 (Part 1) and Phase 2
AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An AE was considered treatment emergent if occurred for the first time after the start of study treatment or occurred prior to the start of treatment but increased in NCI CTCAE version 4.0 grade during study treatment period. AE severity was defined to be the maximum toxicity grade of the TEAEs experienced by the participants during the study. AE was assessed according to severity as: Grade 1 (mild AE), Grade 2 (moderate AE), Grade 3 (severe AE), Grade 4 (life-threatening consequences) and Grade 5 (death related to AE).
Time frame: Part 1 Phase 1: Lead-in period (Day -7) up to 28 days after last dose of study drug (up to 308 days), Phase 2: Baseline (Day 1) up to 28 days after last dose of study drug (up to 1526 days)
Number of Participants With Clinically Significant Laboratory Abnormalities
Abnormality criteria: hemoglobin: \<0.8\*lower limit of normal \[LLN\], platelets: \<0.5\*LLN or \>1.75\*upper limit of normal \[ULN\], leukocytes: \<0.6\*LLN or \>1.5\*ULN, lymphocytes, total neutrophils: \<0.8\*LLN or \>1.2\*ULN, basophils, eosinophil,monocytes: \>1.2\*ULN); aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, gamma glutamyl transferase (GT): \>0.3\*ULN, total protein, albumin: \<0.8\*LLN or \>1.2\*ULN, total bilirubin, direct bilirubin: \>1.5\*ULN; blood urea nitrogen, creatinine: \>1.3\*ULN, uric acid: \>1.2\*ULN; sodium: \<0.95\*LLN or \>1.05\*ULN, potassium, chloride, calcium, magnesium: \<0.9\*LLN or \>1.1\*ULN, phosphate: \<0.8\*LLN or \>1.2\*ULN; creatine kinase: \>2.0\*ULN, glucose fasting: \<0.6\*LLN or \>1.5\*ULN, glycosylated haemoglobin: \>1.3\*ULN;urinalysis dipstick (urine protein, urine blood \>=1); urine protein 24 hour: \>1.1\*ULN; coagulation Activated partial thromboplastin time \[APTT\], Prothrombin, prothrombin international ratio: \>1.1\*ULN.
Time frame: Part 1 Phase 1: Lead-in period (Day -7) up to 308 days; Part 2 Phase 1: Baseline (Day 1) up to 1673 days; Phase 2: Baseline (Day 1) up to 1526 days
Area Under the Plasma Concentration Time Curve Over Dosing Interval (AUCtau) of PD-0332991 Following Multiple Dose: Part 1 Phase 1
AUCtau is area under the plasma concentration-time curve over dosing interval which is calculated by log-linear trapezoidal method.
Time frame: Multiple dose: 0 hour (pre-dose), 1, 2, 4, 6, 8, 12, 24 hours post-dose on Cycle 1 Day 8
AUCtau Dose Normalized to 125 Milligram (mg) of PD-0332991 Following Multiple Dose: Part 1 Phase 1
AUCtau Dose Normalized to 125 mg is area under the plasma concentration-time curve over dosing interval dose normalized to 125 mg which is calculated by log-linear trapezoidal method.
Time frame: Multiple dose: 0 hour (pre-dose), 1, 2, 4, 6, 8, 12, 24 hours post-dose on Cycle 1 Day 8
Area Under the Plasma Concentration-Time Curve From 0 to Time 24 Hours (AUC24) of PD-0332991 Following Single Dose: Part 1 Phase 1
AUC24 is area under the plasma concentration-time curve from 0 to time 24 hours which is calculated by log-linear trapezoidal method.
Time frame: Single dose: 0 hour (pre-dose), 1, 2, 4, 6, 8, 12 and 24 hours post-dose in Lead-in period (Day -7)
AUC24 Dose Normalized to 125 mg of PD-0332991 Following Single Dose: Part 1 Phase 1
AUC24 Dose Normalized to 125 mg is area under the plasma concentration-time curve from 0 to time 24 hours dose normalized to 125 mg which is calculated by log-linear trapezoidal method.
Time frame: Single dose: 0 hour (pre-dose), 1, 2, 4, 6, 8, 12 and 24 hours post-dose in Lead-in period (Day -7)
Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUCinf) of PD-0332991 Following Single Dose: Part 1 Phase 1
AUCinf is area under the plasma concentration-time curve from 0 to infinity which is calculated by log-linear trapezoidal method.
Time frame: Single dose: 0 hour (pre-dose), 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose in Lead-in period (Day -7)
AUCinf Dose Normalized to 125 mg of PD-0332991 Following Single Dose: Part 1 Phase 1
AUCinf Dose Normalized to 125 mg is area under the plasma concentration-time curve from 0 to infinity dose normalized to 125 mg which is calculated by log-linear trapezoidal method.
Time frame: Single dose: 0 hour (pre-dose), 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose in Lead-in period (Day -7)
Area Under the Plasma Concentration-Time Curve From 0 to Time of Last Measurable Concentration (AUClast) of PD-0332991 Following Single Dose: Part 1 Phase 1
AUClast is area under the plasma concentration-time curve from 0 to time of last measurable concentration which is calculated by log-linear trapezoidal method.
Time frame: Single dose: 0 hour (pre-dose), 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose in Lead-in period (Day -7)
AUClast Dose Normalized to 125 mg of PD-0332991 Following Single Dose: Part 1 Phase 1
AUClast Dose Normalized to 125 mg is area under the plasma concentration-time curve from 0 to time of last measurable concentration dose normalized to 125 mg which is calculated by log-linear trapezoidal method.
Time frame: Single dose: 0 hour (pre-dose), 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose in Lead-in period (Day -7)
Apparent Oral Clearance of PD-0332991: Part 1 Phase 1
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. It was calculated by dividing the given oral dose by AUCinf. AUCinf is area under the plasma concentration-time curve from 0 to infinity which is calculated by log-linear trapezoidal method.
Time frame: Single dose: 0 hour (pre-dose),1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose in Lead-in period (Day -7), Multiple dose: 0 hour (pre-dose), 1, 2, 4, 6, 8, 12, 24 hours post-dose on Cycle 1 Day 8
Maximum Observed Plasma Concentration (Cmax) Of PD-0332991: Part 1 Phase 1
Cmax is maximum plasma concentration which is observed directly from the actual time-concentration data.
Time frame: Single dose: 0 hour (pre-dose),1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose in Lead-in period (Day -7), Multiple dose: 0 hour (pre-dose), 1, 2, 4, 6, 8, 12, 24 hours post-dose on Cycle 1 Day 8
Cmax Dose Normalized to 125 mg of PD-0332991: Part 1 Phase 1
Cmax Dose Normalized to 125 mg is maximum plasma concentration dose normalized to 125 mg which is observed directly from the actual time-concentration data.
Time frame: Single dose: 0 hour (pre-dose),1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose in Lead-in period (Day -7), Multiple dose: 0 hour (pre-dose), 1, 2, 4, 6, 8, 12, 24 hours post-dose on Cycle 1 Day 8
Pre-dose Plasma Concentration (Ctrough) of PD-0332991 Following Multiple Dose: Part 1 Phase 1
Ctrough is pre-dose concentration during multiple dosing which is observed directly from the actual time-concentration data.
Time frame: Multiple dose: 0 hour (pre-dose), 1, 2, 4, 6, 8, 12, 24 hours post-dose on Cycle 1 Day 8
Accumulation Ratio (Rac) of PD-0332991 Following Multiple Dose: Part 1 Phase 1
Rac is the ratio of AUCtau (after multiple doses) to AUCtau (after single dose). AUCtau is area under the plasma concentration-time curve over dosing interval which is calculated by log-linear trapezoidal method.
Time frame: Single dose: 0 hour (pre-dose), 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose in Lead-in period (Day -7), Multiple dose: 0 hour (pre-dose), 1, 2, 4, 6, 8, 12, 24 hours post-dose on Cycle 1 Day 8
Linearity (Rss) of PD-0332991 Following Multiple Dose: Part 1 Phase 1
Rss is the ratio of AUCtau (after multiple doses) to AUCinf (after single dose). AUCtau is area under the plasma concentration-time curve over dosing interval which is calculated by log-linear trapezoidal method. AUCinf is area under the plasma concentration-time curve from 0 to infinity which is calculated by log-linear trapezoidal method.
Time frame: Single dose: 0 hour (pre-dose), 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose in Lead-in period (Day -7), Multiple dose: 0 hour (pre-dose), 1, 2, 4, 6, 8, 12, 24 hours post-dose on Cycle 1 Day 8
Time to Reach Maximum Observed Plasma Concentration (Tmax) of PD-0332991: Part 1 Phase 1
Tmax is time at which maximum plasma concentration (Cmax) was observed. It was observed directly from data as time of first occurrence.
Time frame: Single dose: 0 hour (pre-dose),1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose in Lead-in period (Day -7), Multiple dose: 0 hour (pre-dose), 1, 2, 4, 6, 8, 12, 24 hours post-dose on Cycle 1 Day 8
Terminal Half-Life (t1/2) of PD-0332991: Part 1 Phase 1
t1/2 is terminal elimination half-life which is calculated by loge(2)/kel, where kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.
Time frame: Single dose: 0 hour (pre-dose),1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose in Lead-in period (Day -7), Multiple dose: 0 hour (pre-dose), 1, 2, 4, 6, 8, 12, 24 hours post-dose on Cycle 1 Day 8
Volume of Distribution (Vz/F) of PD-0332991 Following Single Dose: Part 1 Phase 1
Vz/F is apparent volume of distribution estimated from terminal phase, which is calculated as CL/F/kel. Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. It was calculated by dividing the given oral dose by area under the plasma concentration-time curve from 0 to infinity which is calculated by log-linear trapezoidal method (AUCinf). kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.
Time frame: Single dose: 0 hour (pre-dose), 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose in Lead-in period (Day -7)
Area Under the Plasma Concentration Time Curve Over Dosing Interval (AUCtau) of PD-0332991: Phase 2
AUCtau is area under the plasma concentration-time curve over dosing interval which is calculated by log-linear trapezoidal method.
Time frame: 0 (pre-dose), 1, 2, 4, 6, 8, 10, 24 hours post dose on Cycle 1 Day 15
Apparent Oral Clearance of PD-0332991: Phase 2
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. It was calculated by dividing the given oral dose by AUCtau. AUCtau is the area under the plasma concentration-time curve over dosing interval which is calculated by log-linear trapezoidal method.
Time frame: 0 (pre-dose), 1, 2, 4, 6, 8, 10, 24 hours post dose on Cycle 1 Day 15
Maximum Observed Plasma Concentration (Cmax) Of PD-0332991: Phase 2
Cmax is maximum plasma concentration which is observed directly from the actual time-concentration data.
Time frame: 0 (pre-dose), 1, 2, 4, 6, 8, 10, 24 hours post dose on Cycle 1 Day 15
Time to Reach Maximum Observed Plasma Concentration (Tmax) of PD-0332991: Phase 2
Tmax is time at which maximum plasma concentration (Cmax) was observed. It was observed directly from data as time of first occurrence.
Time frame: 0 (pre-dose), 1, 2, 4, 6, 8, 10, 24 hours post dose on Cycle 1 Day 15
Pre-dose Plasma Concentration (Ctrough) of PD-0332991: Phase 2
Ctrough is pre-dose concentration during multiple dosing which is observed directly from the actual time-concentration data.
Time frame: 0 (pre-dose), 1, 2, 4, 6, 8, 10, 24 hours post dose on Cycle 1 Day 15
Percentage of Participants With Objective Response: Phase 1
Objective response (OR) was defined as a complete response (CR) or partial response (PR) according to the RECIST version 1.1 recorded from first dose of study treatment until disease progression or death due to any cause. CR was defined as disappearance of all target lesions with the exception of nodal disease. All target nodes reduced to normal size (short axis \<10 millimeter \[mm\]). PR was defined as a \>=30 percent decrease in sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. Percentage of participants with objective response (who achieved CR or PR) were reported.
Time frame: From initiation of treatment up to disease progression (up to 30 months)
Percentage of Participants With Objective Response: Phase 2
Objective response was defined as a complete response (CR) or partial response (PR) according to the RECIST version 1.1 recorded from first dose of study treatment until disease progression or death due to any cause. PD was defined using RECIST v1.1, as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. CR was defined as disappearance of all target lesions with the exception of nodal disease. All target nodes reduced to normal size (short axis \<10 mm). PR was defined as a \>=30% decrease in sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. Percentage of participants with objective response (who achieved CR or PR) were reported.
Time frame: From initiation of treatment up to disease progression (up to 1526 days)
Duration of Response (DOR): Part 2 Phase 1
Duration of response was defined as the interval from the first documentation of objective tumor response in participants with CR (disappearance of all target lesions with the exception of nodal disease. All target nodes reduced to normal size (short axis \<10 millimeter \[mm\]) or PR (a \>=30 percent decrease in sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions) according to RECIST version 1.1 to the first documentation of objective tumor progression or to death due to any cause, whichever occurred first.
Time frame: baseline up to 1673 days
Duration of Response (DOR): Phase 2
Duration of response was defined as the interval from the first documentation of objective tumor response in participants with CR (disappearance of all target lesions with the exception of nodal disease, all target nodes reduced to normal size (short axis \<10 mm) or PR (a \>=30 % decrease in sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions) according to RECIST version 1.1 to the first documentation of objective tumor progression or to death due to any cause, whichever occurred first. PD was defined using RECIST v1.1, as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
Time frame: From initiation of treatment up to disease progression (up to 1526 days)
Progression Free Survival (PFS): Part 2 Phase 1
PFS was defined as the time from first dose of study treatment to the date of the first documentation of objective progression of disease (PD) or death due to any cause in the absence of documented PD, whichever occurs first. PD was defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
Time frame: baseline up to 1673 days
Percentage of Participants With Disease Control (DC): Phase 2
DC: CR, PR or stable disease (SD) for \>=24 weeks according to RECIST version (v)1.1 recorded in time period between first dose of study treatment and disease progression or death to any cause. CR: disappearance of all target lesions with exception of nodal disease. All target nodes reduced to normal size (short axis \<10 mm). PR: \>=30% decrease in sum of longest dimensions of target lesions taking as a reference baseline sum longest dimensions. SD was defined as not achieving an OR with confirmed CR or PR according to RECIST v1.1, as determined by investigators, relative to response evaluable population, but remained stable for at least 24 weeks after first dose, then best overall response for such a participant was considered as stable disease. PD was defined using RECIST v1.1 as a 20% increase in sum of longest diameter of target lesions, or a measurable increase in a non-target lesion, or appearance of new lesions.
Time frame: From initiation of treatment up to disease progression (up to 1526 days)
Overall Survival (OS): Phase 2
Overall survival was defined as the time from first dose of study treatment to date of death due to any cause. In the absence of confirmation of death, survival time was censored to last date the participant was known to be alive. OS was estimated with Kaplan-Meier method.
Time frame: From initiation of treatment up to follow-up period (up to 1526 days)
Change From Baseline in Functional Assessment of Cancer Therapy-Breast Cancer (FACT-B): Phase 2 at Day 1 of Cycle 2, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49 and End of Treatment
The functional assessment of cancer therapy (FACT) is a modular approach to assess participant's health-related quality of life. FACT-B total score was derived from the sum of these 5 sub-scale scores: physical well-being, social/family well-being and functional well-being (all 3 sub-scales consisting of 7 items ranging from 0 to 28, where higher scores indicating better quality of life), emotional well-being (consists of 6 items and ranging from 0 to 24, where higher scores indicating better quality of life, and a breast cancer subscale (consists of 9 items and ranging from 0 to 36, where higher scores indicating better quality of life). Each individual item was rated on a 5-point Likert scale, ranging from 0 (not at all good) to 4 (very well), where higher scores indicating better quality of life. FACT-B total score range was of 0 (not at all good) to 144 (very well), where higher scores indicating better quality of life.
Time frame: Baseline (Day 1 of Cycle 1), Day 1 of Cycle 2, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, End of treatment (up to 1526 days)
Change From Baseline in Functional Assessment of Cancer Therapy-General (FACT-G): Phase 2 at Day 1 of Cycle 2, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49 and End of Treatment
FACT is a modular approach to assess participant's health-related quality of life. FACT-G total score was derived from the sum of these 4 sub-scale scores: physical well-being, social/family well-being and functional well-being (all 3 sub-scales consisting of 7 items ranging from 0 to 28, where higher scores indicating better quality of life), emotional well-being (consists of 6 items and ranging from 0 to 24, where higher scores indicating better quality of life). Each individual item was rated on a 5-point Likert scale, ranging from 0 (not at all good) to 4 (very well), where higher scores indicating better quality of life. FACT-G total score range was of 0 (not at all good) to 108 (very well), where higher scores indicating better quality of life.
Time frame: Baseline (Day 1 of Cycle 1), Day 1 of Cycle 2, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, End of treatment (up to 1526 days)
Change From Baseline in Trial Outcome Index (TOI): Phase 2 at Day 1 of Cycle 2, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49 and End of Treatment
FACT is a modular approach to assess participant's health-related quality of life. TOI total score was derived from the sum of the 3 sub-scale scores: physical well-being, functional well-being (both sub-scales consisting of 7 items ranging from 0 to 28, where higher scores indicating better quality of life) and breast cancer subscale (consists of 9 items and ranging from 0 to 36, where higher scores indicating better quality of life). Each individual item was rated on a 5-point Likert scale, ranging from 0 (not at all good) to 4 (very well), where higher scores indicating better quality of life. TOI total score range was of 0 (not at all good) to 92 (very well), where higher scores indicating better quality of life.
Time frame: Baseline (Day 1 of Cycle 1), Day 1 of Cycle 2, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, End of treatment (up to 1526 days)
Presence of Tumor Tissue Biomarker- Ki67: Phase 2
Tumor tissue biomarker, Ki67 was analyzed to investigate possible associations with resistance or sensitivity to treatment with study drugs and was selected based on its known relevance to mechanisms involved in cell cycle regulation. Number of participants with less than or equal to and greater than 20 percent of Ki67 tumor tissue biomarker were reported.
Time frame: Baseline (Day 1)
Presence of Tumor Tissue Biomarkers- Estrogen Receptor (ER) H-Score, Retinoblastoma (Rb) H-Score, B-cell Lymphoma-1 (BCL-1) H-Score, P16 H-Score: Phase 2
Tumor tissue biomarkers ER, Rb, BCL-1 and P16 were analyzed to investigate possible associations with resistance or sensitivity to treatment with study drugs and were selected based on their known relevance to mechanisms involved in cell cycle regulation. Number of participants with positive ER (H-Score), Rb (H-Score), BCL-1 (H-Score) and P16 (H-Score) tumor tissue biomarkers were reported. The H-score is a method of assessing the extent of nuclear immunoreactivity, applicable to steroid receptors.
Time frame: Baseline (Day 1)
| Milestone | PD-0332991 100 mg: Dose Escalation Cohort | PD-0332991 125 mg: Dose Escalation Cohort | PD-0332991 125 mg+ Letrozole 2.5 mg: MTD Cohort | PD-0332991 125 mg+ Letrozole 2.5 mg: Expanded Cohort |
|---|---|---|---|---|
| Started | 6 | 6 | 0 | 0 |
| Treated | 6 | 6 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 6 | 6 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 |
| Withdrew: Objective progression or relapse | 5 | 6 | 0 | 0 |
| Milestone | PD-0332991 100 mg: Dose Escalation Cohort | PD-0332991 125 mg: Dose Escalation Cohort | PD-0332991 125 mg+ Letrozole 2.5 mg: MTD Cohort | PD-0332991 125 mg+ Letrozole 2.5 mg: Expanded Cohort |
|---|---|---|---|---|
| Started | 0 | 0 | 6 | 0 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 6 | 0 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 |
| Withdrew: Commercial avaliabity of palbociclib | 0 | 0 | 4 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 |
| Milestone | PD-0332991 100 mg: Dose Escalation Cohort | PD-0332991 125 mg: Dose Escalation Cohort | PD-0332991 125 mg+ Letrozole 2.5 mg: MTD Cohort | PD-0332991 125 mg+ Letrozole 2.5 mg: Expanded Cohort |
|---|---|---|---|---|
| Started | 0 | 0 | 0 | 43 |
| Treated | 0 | 0 | 0 | 42 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 43 |
| Withdrew: Death | 0 | 0 | 0 | 8 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 0 | 30 |
| Withdrew: Enrolled but not treated | 0 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 4 |
DLT was classified as per common terminology criteria for adverse events (CTCAE) version 4.0 as any of the events occurring during 28 days of Cycle 1,attributed to study drug:grade 4 neutropenia(for a duration of greater than \[\>\]7 days); febrile neutropenia (grade greater than or equal to \[\>=\]3 neutropenia,body temperature \>=38.5 degree Celsius);grade \>=3 thrombocytopenia with bleeding episode;grade 4 thrombocytopenia;grade \>=3 non-hematologic toxicity except grade 3 or more nausea, vomiting,electrolyte abnormality(if controllable by therapy);grade 3 QTc prolongation(\>500 millisecond \[msec\])persist after correction of reversible cause such as electrolyte abnormalities or hypoxia. Lack of hematologic recovery (platelets less than \[\<\]50,000/microliter \[mcL\],absolute neutrophil count \<1,000/mcL,hemoglobin \<8.0 gram/deciliter \[g/dL\]) or prolonged non hematologic toxicities that delays initiation of next dose by \>7 days;receipt of \<75 percent of planned dose in first cycle due to toxicity.
| Participants | PD-0332991 100 mg: Dose Escalation Cohort | PD-0332991 125 mg: Dose Escalation Cohort |
|---|---|---|
| Number of Participants With Dose Limiting Toxicities (DLT): Part 1 Phase 1 | 1 | 1 |
A treatment related AE is any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event had a causal relationship with the treatment or usage. A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Relatedness was judged by investigator. AEs included both serious and non-serious adverse events.
| Participants | PD-0332991 125 mg+ Letrozole 2.5 mg: MTD Cohort |
|---|---|
| AEs | 6 |
| SAEs | 2 |
AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An AE was considered treatment emergent if occurred for the first time after the start of study treatment or occurred prior to the start of treatment but increased in National Cancer Institute (NCI) CTCAE grade during study treatment period. AE severity was defined to be the maximum toxicity grade of the TEAEs experienced by the participants during the study. AE was assessed according to severity as: Grade 1 (mild AE), Grade 2 (moderate AE), Grade 3 (severe AE), Grade 4 (life-threatening consequences) and Grade 5 (death related to AE).
| Participants | PD-0332991 125 mg+ Letrozole 2.5 mg: MTD Cohort |
|---|---|
| Grade 1 | 0 |
| Grade 2 | 0 |
| Grade 3 | 4 |
| Grade 4 | 2 |
| Grade 5 | 0 |
PFS was defined as the time from first dose of study treatment to the date of the first documentation of objective progression of disease (PD) or death due to any cause in the absence of documented PD, whichever occurred first. PD was defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.1-year PFS was defined as the percentage of participants without PFS events (PD or death due to any cause) at 12 months based on the Kaplan-Meier estimate. Percentage of participants with 1-year PFS with 90% confidence interval (CI) were reported.
| percentage of participants | PD-0332991 125 mg+ Letrozole 2.5 mg: Expanded Cohort |
|---|---|
| Percentage of Participants With 1 Year Progression Free Survival (PFS): Phase 2 | 75.6 (62.4 to 84.7) |
A treatment related AE is any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event had a causal relationship with the treatment or usage. A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Relatedness was judged by investigator. AEs included both serious and non-serious adverse events.
| Participants | PD-0332991 100 mg: Dose Escalation Cohort | PD-0332991 125 mg: Dose Escalation Cohort | PD-0332991 125 mg+ Letrozole 2.5 mg: Expanded Cohort |
|---|---|---|---|
| AEs | 6 | 5 | 42 |
| SAEs | 0 | 0 | 2 |
AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An AE was considered treatment emergent if occurred for the first time after the start of study treatment or occurred prior to the start of treatment but increased in NCI CTCAE version 4.0 grade during study treatment period. AE severity was defined to be the maximum toxicity grade of the TEAEs experienced by the participants during the study. AE was assessed according to severity as: Grade 1 (mild AE), Grade 2 (moderate AE), Grade 3 (severe AE), Grade 4 (life-threatening consequences) and Grade 5 (death related to AE).
| Participants | PD-0332991 100 mg: Dose Escalation Cohort | PD-0332991 125 mg: Dose Escalation Cohort | PD-0332991 125 mg+ Letrozole 2.5 mg: Expanded Cohort |
|---|---|---|---|
| Grade 1 | 0 | 1 | 0 |
| Grade 2 | 0 | 1 | 2 |
| Grade 3 | 4 | 3 | 29 |
| Grade 4 | 2 | 1 | 10 |
| Grade 5 | 0 | 0 | 1 |
Abnormality criteria: hemoglobin: \<0.8\*lower limit of normal \[LLN\], platelets: \<0.5\*LLN or \>1.75\*upper limit of normal \[ULN\], leukocytes: \<0.6\*LLN or \>1.5\*ULN, lymphocytes, total neutrophils: \<0.8\*LLN or \>1.2\*ULN, basophils, eosinophil,monocytes: \>1.2\*ULN); aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, gamma glutamyl transferase (GT): \>0.3\*ULN, total protein, albumin: \<0.8\*LLN or \>1.2\*ULN, total bilirubin, direct bilirubin: \>1.5\*ULN; blood urea nitrogen, creatinine: \>1.3\*ULN, uric acid: \>1.2\*ULN; sodium: \<0.95\*LLN or \>1.05\*ULN, potassium, chloride, calcium, magnesium: \<0.9\*LLN or \>1.1\*ULN, phosphate: \<0.8\*LLN or \>1.2\*ULN; creatine kinase: \>2.0\*ULN, glucose fasting: \<0.6\*LLN or \>1.5\*ULN, glycosylated haemoglobin: \>1.3\*ULN;urinalysis dipstick (urine protein, urine blood \>=1); urine protein 24 hour: \>1.1\*ULN; coagulation Activated partial thromboplastin time \[APTT\], Prothrombin, prothrombin international ratio: \>1.1\*ULN.
| Participants | PD-0332991 100 mg: Dose Escalation Cohort | PD-0332991 125 mg: Dose Escalation Cohort | PD-0332991 125 mg+ Letrozole 2.5 mg: MTD Cohort | PD-0332991 125 mg+ Letrozole 2.5 mg: Expanded Cohort |
|---|---|---|---|---|
| Number of Participants With Clinically Significant Laboratory Abnormalities | 6 | 6 | 6 | 40 |
AUCtau is area under the plasma concentration-time curve over dosing interval which is calculated by log-linear trapezoidal method.
| nanogram*hour per milliliter (ng*hr/mL) | PD-0332991 100 mg: Dose Escalation Cohort | PD-0332991 125 mg: Dose Escalation Cohort |
|---|---|---|
| Area Under the Plasma Concentration Time Curve Over Dosing Interval (AUCtau) of PD-0332991 Following Multiple Dose: Part 1 Phase 1 | 1276 ± 45 | 2838 ± 43 |
AUCtau Dose Normalized to 125 mg is area under the plasma concentration-time curve over dosing interval dose normalized to 125 mg which is calculated by log-linear trapezoidal method.
| ng*hr/mL | PD-0332991 100 mg: Dose Escalation Cohort | PD-0332991 125 mg: Dose Escalation Cohort |
|---|---|---|
| AUCtau Dose Normalized to 125 Milligram (mg) of PD-0332991 Following Multiple Dose: Part 1 Phase 1 | 1595 ± 45 | 2838 ± 43 |
AUC24 is area under the plasma concentration-time curve from 0 to time 24 hours which is calculated by log-linear trapezoidal method.
| ng*hr/mL | PD-0332991 100 mg: Dose Escalation Cohort | PD-0332991 125 mg: Dose Escalation Cohort |
|---|---|---|
| Area Under the Plasma Concentration-Time Curve From 0 to Time 24 Hours (AUC24) of PD-0332991 Following Single Dose: Part 1 Phase 1 | 547.5 ± 19 | 1322 ± 42 |
AUC24 Dose Normalized to 125 mg is area under the plasma concentration-time curve from 0 to time 24 hours dose normalized to 125 mg which is calculated by log-linear trapezoidal method.
| ng*hr/mL | PD-0332991 100 mg: Dose Escalation Cohort | PD-0332991 125 mg: Dose Escalation Cohort |
|---|---|---|
| AUC24 Dose Normalized to 125 mg of PD-0332991 Following Single Dose: Part 1 Phase 1 | 684.5 ± 19 | 1322 ± 42 |
AUCinf is area under the plasma concentration-time curve from 0 to infinity which is calculated by log-linear trapezoidal method.
| ng*hr/mL | PD-0332991 100 mg: Dose Escalation Cohort | PD-0332991 125 mg: Dose Escalation Cohort |
|---|---|---|
| Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUCinf) of PD-0332991 Following Single Dose: Part 1 Phase 1 | 1039 ± 32 | 2483 ± 49 |
AUCinf Dose Normalized to 125 mg is area under the plasma concentration-time curve from 0 to infinity dose normalized to 125 mg which is calculated by log-linear trapezoidal method.
| ng*hr/mL | PD-0332991 100 mg: Dose Escalation Cohort | PD-0332991 125 mg: Dose Escalation Cohort |
|---|---|---|
| AUCinf Dose Normalized to 125 mg of PD-0332991 Following Single Dose: Part 1 Phase 1 | 1296 ± 32 | 2483 ± 49 |
AUClast is area under the plasma concentration-time curve from 0 to time of last measurable concentration which is calculated by log-linear trapezoidal method.
| ng*hr/mL | PD-0332991 100 mg: Dose Escalation Cohort | PD-0332991 125 mg: Dose Escalation Cohort |
|---|---|---|
| Area Under the Plasma Concentration-Time Curve From 0 to Time of Last Measurable Concentration (AUClast) of PD-0332991 Following Single Dose: Part 1 Phase 1 | 971.7 ± 31 | 2396 ± 48 |
AUClast Dose Normalized to 125 mg is area under the plasma concentration-time curve from 0 to time of last measurable concentration dose normalized to 125 mg which is calculated by log-linear trapezoidal method.
| ng*hr/mL | PD-0332991 100 mg: Dose Escalation Cohort | PD-0332991 125 mg: Dose Escalation Cohort |
|---|---|---|
| AUClast Dose Normalized to 125 mg of PD-0332991 Following Single Dose: Part 1 Phase 1 | 1215 ± 31 | 2396 ± 48 |
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. It was calculated by dividing the given oral dose by AUCinf. AUCinf is area under the plasma concentration-time curve from 0 to infinity which is calculated by log-linear trapezoidal method.
| liter per hour (L/hr) | PD-0332991 100 mg: Dose Escalation Cohort | PD-0332991 125 mg: Dose Escalation Cohort |
|---|---|---|
| Single dose | 96.43 ± 32 | 50.29 ± 49 |
| Multiple dose | 78.43 ± 45 | 44.03 ± 43 |
Cmax is maximum plasma concentration which is observed directly from the actual time-concentration data.
| nanogram per milliliter (ng/mL) | PD-0332991 100 mg: Dose Escalation Cohort | PD-0332991 125 mg: Dose Escalation Cohort |
|---|---|---|
| Single dose | 41.37 ± 15 | 104.1 ± 39 |
| Multiple dose | 77.36 ± 33 | 185.5 ± 27 |
Cmax Dose Normalized to 125 mg is maximum plasma concentration dose normalized to 125 mg which is observed directly from the actual time-concentration data.
| ng/mL | PD-0332991 100 mg: Dose Escalation Cohort | PD-0332991 125 mg: Dose Escalation Cohort |
|---|---|---|
| Single dose | 51.74 ± 15 | 104.1 ± 39 |
| Multiple dose | 96.72 ± 33 | 185.5 ± 27 |
Ctrough is pre-dose concentration during multiple dosing which is observed directly from the actual time-concentration data.
| ng/mL | PD-0332991 100 mg: Dose Escalation Cohort | PD-0332991 125 mg: Dose Escalation Cohort |
|---|---|---|
| Pre-dose Plasma Concentration (Ctrough) of PD-0332991 Following Multiple Dose: Part 1 Phase 1 | 35.51 ± 59 | 72.76 ± 48 |
Rac is the ratio of AUCtau (after multiple doses) to AUCtau (after single dose). AUCtau is area under the plasma concentration-time curve over dosing interval which is calculated by log-linear trapezoidal method.
| ratio | PD-0332991 100 mg: Dose Escalation Cohort | PD-0332991 125 mg: Dose Escalation Cohort |
|---|---|---|
| Accumulation Ratio (Rac) of PD-0332991 Following Multiple Dose: Part 1 Phase 1 | 2.060 (1.81 to 3.54) | 1.855 (1.74 to 3.10) |
Rss is the ratio of AUCtau (after multiple doses) to AUCinf (after single dose). AUCtau is area under the plasma concentration-time curve over dosing interval which is calculated by log-linear trapezoidal method. AUCinf is area under the plasma concentration-time curve from 0 to infinity which is calculated by log-linear trapezoidal method.
| ratio | PD-0332991 100 mg: Dose Escalation Cohort | PD-0332991 125 mg: Dose Escalation Cohort |
|---|---|---|
| Linearity (Rss) of PD-0332991 Following Multiple Dose: Part 1 Phase 1 | 1.130 (1.03 to 1.73) | 1.105 (0.851 to 1.51) |
Tmax is time at which maximum plasma concentration (Cmax) was observed. It was observed directly from data as time of first occurrence.
| hour | PD-0332991 100 mg: Dose Escalation Cohort | PD-0332991 125 mg: Dose Escalation Cohort |
|---|---|---|
| Single dose | 5.02 (3.97 to 8.02) | 4.00 (3.90 to 8.00) |
| Multiple dose | 4.02 (3.97 to 6.00) | 4.02 (3.95 to 6.02) |
t1/2 is terminal elimination half-life which is calculated by loge(2)/kel, where kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.
| hour | PD-0332991 100 mg: Dose Escalation Cohort | PD-0332991 125 mg: Dose Escalation Cohort |
|---|---|---|
| Single dose | 25.72 ± 5.2632 | 23.93 ± 2.6882 |
| Multiple dose | 23.75 ± 6.7778 | 23.15 ± 7.7045 |
Vz/F is apparent volume of distribution estimated from terminal phase, which is calculated as CL/F/kel. Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. It was calculated by dividing the given oral dose by area under the plasma concentration-time curve from 0 to infinity which is calculated by log-linear trapezoidal method (AUCinf). kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.
| liter | PD-0332991 100 mg: Dose Escalation Cohort | PD-0332991 125 mg: Dose Escalation Cohort |
|---|---|---|
| Volume of Distribution (Vz/F) of PD-0332991 Following Single Dose: Part 1 Phase 1 | 3514 ± 25 | 1730 ± 41 |
AUCtau is area under the plasma concentration-time curve over dosing interval which is calculated by log-linear trapezoidal method.
| ng*hr/mL | PD-0332991 125 mg+ Letrozole 2.5 mg: Expanded Cohort |
|---|---|
| Area Under the Plasma Concentration Time Curve Over Dosing Interval (AUCtau) of PD-0332991: Phase 2 | 1979 ± 16 |
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. It was calculated by dividing the given oral dose by AUCtau. AUCtau is the area under the plasma concentration-time curve over dosing interval which is calculated by log-linear trapezoidal method.
| L/hr | PD-0332991 125 mg+ Letrozole 2.5 mg: Expanded Cohort |
|---|---|
| Apparent Oral Clearance of PD-0332991: Phase 2 | 63.21 ± 16 |
Cmax is maximum plasma concentration which is observed directly from the actual time-concentration data.
| ng/mL | PD-0332991 125 mg+ Letrozole 2.5 mg: Expanded Cohort |
|---|---|
| Maximum Observed Plasma Concentration (Cmax) Of PD-0332991: Phase 2 | 124.7 ± 26 |
Tmax is time at which maximum plasma concentration (Cmax) was observed. It was observed directly from data as time of first occurrence.
| hour | PD-0332991 125 mg+ Letrozole 2.5 mg: Expanded Cohort |
|---|---|
| Time to Reach Maximum Observed Plasma Concentration (Tmax) of PD-0332991: Phase 2 | 4.90 (2.00 to 8.20) |
Ctrough is pre-dose concentration during multiple dosing which is observed directly from the actual time-concentration data.
| ng/mL | PD-0332991 125 mg+ Letrozole 2.5 mg: Expanded Cohort |
|---|---|
| Pre-dose Plasma Concentration (Ctrough) of PD-0332991: Phase 2 | 59.75 ± 38 |
Objective response (OR) was defined as a complete response (CR) or partial response (PR) according to the RECIST version 1.1 recorded from first dose of study treatment until disease progression or death due to any cause. CR was defined as disappearance of all target lesions with the exception of nodal disease. All target nodes reduced to normal size (short axis \<10 millimeter \[mm\]). PR was defined as a \>=30 percent decrease in sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. Percentage of participants with objective response (who achieved CR or PR) were reported.
| percentage of participants | PD-0332991 100 mg: Dose Escalation Cohort | PD-0332991 125 mg: Dose Escalation Cohort | PD-0332991 125 mg+ Letrozole 2.5 mg: MTD Cohort |
|---|---|---|---|
| With Complete Response | 0 | 0 | 0 |
| With Partial Response | 0 | 0 | 33.3 |
Objective response was defined as a complete response (CR) or partial response (PR) according to the RECIST version 1.1 recorded from first dose of study treatment until disease progression or death due to any cause. PD was defined using RECIST v1.1, as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. CR was defined as disappearance of all target lesions with the exception of nodal disease. All target nodes reduced to normal size (short axis \<10 mm). PR was defined as a \>=30% decrease in sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. Percentage of participants with objective response (who achieved CR or PR) were reported.
| percentage of participants | PD-0332991 125 mg+ Letrozole 2.5 mg: Expanded Cohort |
|---|---|
| Percentage of Participants With Objective Response: Phase 2 | 47.6 |
Duration of response was defined as the interval from the first documentation of objective tumor response in participants with CR (disappearance of all target lesions with the exception of nodal disease. All target nodes reduced to normal size (short axis \<10 millimeter \[mm\]) or PR (a \>=30 percent decrease in sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions) according to RECIST version 1.1 to the first documentation of objective tumor progression or to death due to any cause, whichever occurred first.
| days | PD-0332991 125 mg+ Letrozole 2.5 mg: MTD Cohort |
|---|---|
| Participant 1 | 1509 |
| Participant 2 | 1428 |
Duration of response was defined as the interval from the first documentation of objective tumor response in participants with CR (disappearance of all target lesions with the exception of nodal disease, all target nodes reduced to normal size (short axis \<10 mm) or PR (a \>=30 % decrease in sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions) according to RECIST version 1.1 to the first documentation of objective tumor progression or to death due to any cause, whichever occurred first. PD was defined using RECIST v1.1, as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
| months | PD-0332991 125 mg+ Letrozole 2.5 mg: Expanded Cohort |
|---|---|
| Duration of Response (DOR): Phase 2 | 41.4 (19.0 to NA) |
PFS was defined as the time from first dose of study treatment to the date of the first documentation of objective progression of disease (PD) or death due to any cause in the absence of documented PD, whichever occurs first. PD was defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
| days | PD-0332991 125 mg+ Letrozole 2.5 mg: MTD Cohort |
|---|---|
| Participant 1 | 1590 |
| Participant 2 | 1593 |
| Participant 3 | 1602 |
| Participant 4 | 36 |
| Participant 5 | 31 |
| Participant 6 | 1512 |
DC: CR, PR or stable disease (SD) for \>=24 weeks according to RECIST version (v)1.1 recorded in time period between first dose of study treatment and disease progression or death to any cause. CR: disappearance of all target lesions with exception of nodal disease. All target nodes reduced to normal size (short axis \<10 mm). PR: \>=30% decrease in sum of longest dimensions of target lesions taking as a reference baseline sum longest dimensions. SD was defined as not achieving an OR with confirmed CR or PR according to RECIST v1.1, as determined by investigators, relative to response evaluable population, but remained stable for at least 24 weeks after first dose, then best overall response for such a participant was considered as stable disease. PD was defined using RECIST v1.1 as a 20% increase in sum of longest diameter of target lesions, or a measurable increase in a non-target lesion, or appearance of new lesions.
| percentage of participants | PD-0332991 125 mg+ Letrozole 2.5 mg: Expanded Cohort |
|---|---|
| Percentage of Participants With Disease Control (DC): Phase 2 | 85.7 |
Overall survival was defined as the time from first dose of study treatment to date of death due to any cause. In the absence of confirmation of death, survival time was censored to last date the participant was known to be alive. OS was estimated with Kaplan-Meier method.
| months | PD-0332991 125 mg+ Letrozole 2.5 mg: Expanded Cohort |
|---|---|
| Overall Survival (OS): Phase 2 | NA (47.5 to NA) |
The functional assessment of cancer therapy (FACT) is a modular approach to assess participant's health-related quality of life. FACT-B total score was derived from the sum of these 5 sub-scale scores: physical well-being, social/family well-being and functional well-being (all 3 sub-scales consisting of 7 items ranging from 0 to 28, where higher scores indicating better quality of life), emotional well-being (consists of 6 items and ranging from 0 to 24, where higher scores indicating better quality of life, and a breast cancer subscale (consists of 9 items and ranging from 0 to 36, where higher scores indicating better quality of life). Each individual item was rated on a 5-point Likert scale, ranging from 0 (not at all good) to 4 (very well), where higher scores indicating better quality of life. FACT-B total score range was of 0 (not at all good) to 144 (very well), where higher scores indicating better quality of life.
| units on a scale | PD-0332991 125 mg+ Letrozole 2.5 mg: Expanded Cohort |
|---|---|
| Baseline | 106.46 (101.87 to 111.04) |
| Change at Cycle 2: Day 1 | -1.20 (-4.56 to 2.16) |
| Change at Cycle 3: Day 1 | -2.22 (-6.27 to 1.83) |
| Change at Cycle 5: Day 1 | -2.38 (-6.07 to 1.31) |
| Change at Cycle 7: Day 1 | -4.62 (-8.43 to -0.81) |
| Change at Cycle 9: Day 1 | -4.45 (-7.86 to -1.04) |
| Change at Cycle 11: Day 1 | -4.48 (-7.99 to -0.97) |
| Change at Cycle 13: Day 1 | -6.32 (-10.56 to -2.09) |
| Change at Cycle 15: Day 1 | -4.06 (-7.84 to -0.27) |
| Change at Cycle 17: Day 1 | -6.07 (-9.48 to -2.65) |
| Change at Cycle 19: Day 1 | -7.39 (-12.06 to -2.72) |
| Change at Cycle 21: Day 1 | -5.85 (-10.29 to -1.42) |
| Change at Cycle 23: Day 1 | -5.89 (-10.97 to -0.82) |
| Change at Cycle 25: Day 1 | -4.22 (-8.61 to 0.17) |
| Change at Cycle 27: Day 1 | -4.76 (-9.22 to -0.30) |
| Change at Cycle 29: Day 1 | -6.26 (-10.94 to -1.57) |
| Change at Cycle 31: Day 1 | -5.13 (-9.46 to -0.79) |
| Change at Cycle 33: Day 1 | -7.12 (-11.14 to -3.11) |
| Change at Cycle 35: Day 1 | -7.68 (-11.66 to -3.70) |
| Change at Cycle 37: Day 1 | -8.07 (-12.56 to -3.58) |
| Change at Cycle 39: Day 1 | -6.87 (-10.89 to -2.85) |
| Change at Cycle 41: Day 1 | -5.70 (-11.41 to 0.02) |
| Change at Cycle 43: Day 1 | -10.42 (-17.24 to -3.59) |
| Change at Cycle 45: Day 1 | -7.94 (-26.09 to 10.20) |
| Change at Cycle 47: Day 1 | -8.56 (-22.48 to 5.36) |
| Change at Cycle 49: Day 1 | -10.58 (-66.70 to 45.54) |
| End of Treatment | -9.17 (-13.82 to -4.52) |
FACT is a modular approach to assess participant's health-related quality of life. FACT-G total score was derived from the sum of these 4 sub-scale scores: physical well-being, social/family well-being and functional well-being (all 3 sub-scales consisting of 7 items ranging from 0 to 28, where higher scores indicating better quality of life), emotional well-being (consists of 6 items and ranging from 0 to 24, where higher scores indicating better quality of life). Each individual item was rated on a 5-point Likert scale, ranging from 0 (not at all good) to 4 (very well), where higher scores indicating better quality of life. FACT-G total score range was of 0 (not at all good) to 108 (very well), where higher scores indicating better quality of life.
| units on a scale | PD-0332991 125 mg+ Letrozole 2.5 mg: Expanded Cohort |
|---|---|
| Baseline | 80.22 (76.21 to 84.23) |
| Change at Cycle 2: Day 1 | -1.15 (-4.10 to 1.80) |
| Change at Cycle 3: Day 1 | -1.34 (-4.72 to 2.04) |
| Change at Cycle 5: Day 1 | -0.36 (-3.21 to 2.48) |
| Change at Cycle 7: Day 1 | -3.56 (-6.52 to -0.60) |
| Change at Cycle 9: Day 1 | -2.39 (-4.94 to 0.16) |
| Change at Cycle 11: Day 1 | -3.94 (-6.79 to -1.09) |
| Change at Cycle 13: Day 1 | -4.74 (-8.11 to -1.37) |
| Change at Cycle 15: Day 1 | -2.98 (-6.23 to 0.26) |
| Change at Cycle 17: Day 1 | -4.64 (-7.37 to -1.91) |
| Change at Cycle 19: Day 1 | -5.48 (-8.94 to -2.01) |
| Change at Cycle 21: Day 1 | -4.34 (-7.94 to -0.74) |
| Change at Cycle 23: Day 1 | -4.39 (-8.42 to -0.37) |
| Change at Cycle 25: Day 1 | -3.22 (-6.94 to 0.50) |
| Change at Cycle 27: Day 1 | -3.80 (-7.34 to -0.26) |
| Change at Cycle 29: Day 1 | -4.52 (-8.58 to -0.45) |
| Change at Cycle 31: Day 1 | -4.55 (-8.27 to -0.84) |
| Change at Cycle 33: Day 1 | -6.67 (-10.26 to -3.08) |
| Change at Cycle 35: Day 1 | -6.63 (-10.38 to -2.88) |
| Change at Cycle 37: Day 1 | -6.49 (-10.52 to -2.46) |
| Change at Cycle 39: Day 1 | -5.07 (-8.37 to -1.76) |
| Change at Cycle 41: Day 1 | -5.06 (-9.92 to -0.20) |
| Change at Cycle 43: Day 1 | -7.08 (-14.53 to 0.37) |
| Change at Cycle 45: Day 1 | -5.94 (-27.36 to 15.47) |
| Change at Cycle 47: Day 1 | -6.22 (-25.11 to 12.66) |
| Change at Cycle 49: Day 1 | -8.58 (-90.11 to 72.95) |
| End of Treatment | -7.09 (-10.98 to -3.20) |
FACT is a modular approach to assess participant's health-related quality of life. TOI total score was derived from the sum of the 3 sub-scale scores: physical well-being, functional well-being (both sub-scales consisting of 7 items ranging from 0 to 28, where higher scores indicating better quality of life) and breast cancer subscale (consists of 9 items and ranging from 0 to 36, where higher scores indicating better quality of life). Each individual item was rated on a 5-point Likert scale, ranging from 0 (not at all good) to 4 (very well), where higher scores indicating better quality of life. TOI total score range was of 0 (not at all good) to 92 (very well), where higher scores indicating better quality of life.
| units on a scale | PD-0332991 125 mg+ Letrozole 2.5 mg: Expanded Cohort |
|---|---|
| Baseline | 71.52 (68.36 to 74.69) |
| Change at Cycle 2: Day 1 | -1.17 (-3.24 to 0.89) |
| Change at Cycle 3: Day 1 | -2.20 (-4.74 to 0.35) |
| Change at Cycle 5: Day 1 | -2.54 (-5.25 to 0.16) |
| Change at Cycle 7: Day 1 | -3.63 (-6.44 to -0.82) |
| Change at Cycle 9: Day 1 | -3.31 (-6.03 to -0.60) |
| Change at Cycle 11: Day 1 | -2.30 (-5.06 to 0.45) |
| Change at Cycle 13: Day 1 | -3.93 (-7.31 to -0.56) |
| Change at Cycle 15: Day 1 | -2.49 (-5.09 to 0.11) |
| Change at Cycle 17: Day 1 | -3.18 (-6.02 to -0.34) |
| Change at Cycle 19: Day 1 | -4.32 (-8.01 to -0.63) |
| Change at Cycle 21: Day 1 | -3.56 (-6.83 to -0.28) |
| Change at Cycle 23: Day 1 | -3.19 (-7.11 to 0.73) |
| Change at Cycle 25: Day 1 | -2.13 (-5.51 to 1.26) |
| Change at Cycle 27: Day 1 | -2.50 (-5.77 to 0.77) |
| Change at Cycle 29: Day 1 | -3.70 (-7.36 to -0.03) |
| Change at Cycle 31: Day 1 | -1.95 (-5.23 to 1.33) |
| Change at Cycle 33: Day 1 | -4.30 (-7.65 to -0.95) |
| Change at Cycle 35: Day 1 | -4.65 (-8.68 to -0.62) |
| Change at Cycle 37: Day 1 | -4.84 (-8.77 to -0.92) |
| Change at Cycle 39: Day 1 | -3.47 (-7.09 to 0.15) |
| Change at Cycle 41: Day 1 | -2.27 (-7.62 to 3.08) |
| Change at Cycle 43: Day 1 | -7.00 (-13.83 to -0.17) |
| Change at Cycle 45: Day 1 | -3.00 (-22.40 to 16.40) |
| Change at Cycle 47: Day 1 | -4.00 (-12.96 to 4.96) |
| Change at Cycle 49: Day 1 | -2.00 (-14.71 to 10.71) |
| End of Treatment | -6.03 (-9.61 to -2.45) |
Tumor tissue biomarker, Ki67 was analyzed to investigate possible associations with resistance or sensitivity to treatment with study drugs and was selected based on its known relevance to mechanisms involved in cell cycle regulation. Number of participants with less than or equal to and greater than 20 percent of Ki67 tumor tissue biomarker were reported.
| participants | PD-0332991 125 mg+ Letrozole 2.5 mg: Expanded Cohort |
|---|---|
| <=20 percent | 19 |
| >20 percent | 23 |
Tumor tissue biomarkers ER, Rb, BCL-1 and P16 were analyzed to investigate possible associations with resistance or sensitivity to treatment with study drugs and were selected based on their known relevance to mechanisms involved in cell cycle regulation. Number of participants with positive ER (H-Score), Rb (H-Score), BCL-1 (H-Score) and P16 (H-Score) tumor tissue biomarkers were reported. The H-score is a method of assessing the extent of nuclear immunoreactivity, applicable to steroid receptors.
| participants | PD-0332991 125 mg+ Letrozole 2.5 mg: Expanded Cohort |
|---|---|
| ER (H-Score) | 41 |
| Rb (H-Score) | 41 |
| BCL-1 (H-Score) | 42 |
| P16 (H-Score) | 41 |
Collected over Part 1 Phase 1: Lead-in period (Day -7) up to 28 days after last dose of study drug (up to 308 days), Part 2 Phase 1: Baseline (Day 1) up to 28 days after last dose of study drug (up to 1673 days), Phase 2: Baseline (Day 1) up to 28 days after last dose of study drug (up to 1526 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PD-0332991 100 mg: Dose Escalation Cohort | — | 0/6 (0%) | 6/6 (100%) |
| PD-0332991 125 mg: Dose Escalation Cohort | — | 0/6 (0%) | 6/6 (100%) |
| PD-0332991 125 mg+ Letrozole 2.5 mg: MTD Cohort | — | 2/6 (33.3%) | 6/6 (100%) |
| PD-0332991 125 mg+ Letrozole 2.5 mg: Expanded Cohort | — | 4/42 (9.5%) | 42/42 (100%) |
| Event | PD-0332991 100 mg: Dose Escalation Cohort | PD-0332991 125 mg: Dose Escalation Cohort | PD-0332991 125 mg+ Letrozole 2.5 mg: MTD Cohort | PD-0332991 125 mg+ Letrozole 2.5 mg: Expanded Cohort |
|---|---|---|---|---|
| Gastrointestinal perforationGastrointestinal disorders | 0/6 | 0/6 | 1/6 | 0/42 |
| Supraventricular tachycardiaCardiac disorders | 0/6 | 0/6 | 1/6 | 0/42 |
| Febrile NeutropeniaBlood and lymphatic system disorders | 0/6 | 0/6 | 0/6 | 1/42 |
| VomitingGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 1/42 |
| MalaiseGeneral disorders | 0/6 | 0/6 | 0/6 | 1/42 |
| Cerebral HaemorrhageNervous system disorders | 0/6 | 0/6 | 0/6 | 1/42 |
| DizzinessNervous system disorders | 0/6 | 0/6 | 0/6 | 1/42 |
| Subarachnoid HaemorrhageNervous system disorders | 0/6 | 0/6 | 0/6 | 1/42 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/6 | 0/6 | 0/6 | 1/42 |
| Event | PD-0332991 100 mg: Dose Escalation Cohort | PD-0332991 125 mg: Dose Escalation Cohort | PD-0332991 125 mg+ Letrozole 2.5 mg: MTD Cohort | PD-0332991 125 mg+ Letrozole 2.5 mg: Expanded Cohort |
|---|---|---|---|---|
| Neutrophil count decreasedInvestigations | 5/6 | 4/6 | 6/6 | 34/42 |
| White blood cell count decreasedInvestigations | 4/6 | 5/6 | 6/6 | 30/42 |
| StomatitisGastrointestinal disorders | 0/6 | 2/6 | 1/6 | 32/42 |
| FallInjury, poisoning and procedural complications | 0/6 | 0/6 | 4/6 | 9/42 |
| Platelet count decreasedInvestigations | 1/6 | 2/6 | 4/6 | 9/42 |
| DiarrhoeaGastrointestinal disorders | 1/6 | 4/6 | 4/6 | 5/42 |
| Lymphocyte count decreasedInvestigations | 1/6 | 3/6 | 0/6 | 2/42 |
| NasopharyngitisInfections and infestations | 1/6 | 0/6 | 2/6 | 19/42 |
| AnaemiaBlood and lymphatic system disorders | 0/6 | 2/6 | 0/6 | 10/42 |
| ConstipationGastrointestinal disorders | 1/6 | 2/6 | 2/6 | 12/42 |
Safety analysis set included all enrolled participants who received at least 1 dose of study drug (PD-0332991).
| Age, Categorical(Participants) | PD-0332991 100 mg: Dose Escalation Cohort | PD-0332991 125 mg: Dose Escalation Cohort | PD-0332991 125 mg+ Letrozole 2.5 mg: MTD Cohort | PD-0332991 125 mg+ Letrozole 2.5 mg: Expanded Cohort | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 4 | 5 | 4 | 26 | 39 |
| >=65 years | 2 | 1 | 2 | 16 | 21 |
| Sex: Female, Male(Participants) | PD-0332991 100 mg: Dose Escalation Cohort | PD-0332991 125 mg: Dose Escalation Cohort | PD-0332991 125 mg+ Letrozole 2.5 mg: MTD Cohort | PD-0332991 125 mg+ Letrozole 2.5 mg: Expanded Cohort | Total |
|---|---|---|---|---|---|
| Female | 5 | 2 | 6 | 42 | 55 |
| Male | 1 | 4 | 0 | 0 | 5 |
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Oct 2012 to primary completion in Mar 2016, 40 months.
Results were first posted in May 2017, 1 year 1 month after primary completion.
Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 40 months is above that.
Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Palbociclib